Genentech, Inc. et al v. Sanofi-Aventis Deutschland GMBH et al
Filing
622
Final JUDGMENT and Certification pursuant to Federal Rule of Civil Procedure 54(b) (SI, COURT STAFF) (Filed on 4/21/2011) Modified on 4/21/2011 (ys, COURT STAFF).
1
2
3
4
5
IN THE UNITED STATES DISTRICT COURT
6
FOR THE NORTHERN DISTRICT OF CALIFORNIA
7
8
GENENTECH, INC., et al.,
9
United States District Court
For the Northern District of California
10
11
12
No. C 08-4909 SI; No. C 09-4919 SI
Plaintiffs,
FINAL JUDGMENT AND
CERTIFICATION PURSUANT TO
FEDERAL RULE OF CIVIL
PROCEDURE 54(b)
v.
SANOFI-AVENTIS DEUTSCHLAND GMBH,
Defendant.
/
13
14
Finding that there is no just reason for delay, and pursuant to Federal Rule of Civil Procedure
15
54(b), the Court enters final judgment of non-infringement of the patents-in-suit as to Rituxan® and
16
Avastin® in favor of Genentech and Biogen Idec. and against Sanofi-Aventis Deutschland GMBH.
17
This is a final, appealable judgment.
18
19
IT IS SO ORDERED AND ADJUDGED.
20
21
22
23
24
25
26
27
28
Dated: April 21, 2011
SUSAN ILLSTON
United States District Judge
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?